http://www.biovalley.com/ The Life Sciences Network Newsfeed en-us BioValley the Trinational Network Fri, 30, Jul 2010 15:09:47 +0100 http://www.biovalley.com/rssfeed.cfm?nid=14551 PARIS - Sanofi-Aventis(SASY.PA) Chief Executive Chris Viehbacher pledged on Thursday to remain disciplined on mergers and acquisitions and stayed silent on plans to buy U.S. biotech Genzyme(GENZ.O). Fri, 30, Jul 2010 14551 http://www.biovalley.com/rssfeed.cfm?nid=14550 MADISON, WI, USA - A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche (SIX: RO, ROG; OTCQX: RHHBY). The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery. Fri, 30, Jul 2010 14550 http://www.biovalley.com/rssfeed.cfm?nid=14549 PHILADELPHIA — Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML). Results are published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Fri, 30, Jul 2010 14549 http://www.biovalley.com/rssfeed.cfm?nid=14548 BASEL, Switzerland -- Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that first results from the TOCCATA observational study were presented at the 22nd Fortbildungswoche für praktische Dermatologie und Venerologie in Munich, Germany. TOCCATA was designed to investigate the clinical profile of Toctino (alitretinoin) under daily practice conditions in severe chronic hand eczema (CHE) patients in Germany. Fri, 30, Jul 2010 14548 http://www.biovalley.com/rssfeed.cfm?nid=14547 YOKOHAMA, Japan – JGC, INPEX and BASF announced today that they have entered into an agreement to jointly carry out demonstration tests on a new technology for effectively capturing and recovering CO2 contained in natural gas. The tests are carried out at INPEX’s Koshijihara natural gas plant (Nagaoka city, Niigata prefecture) starting August 2010. Fri, 30, Jul 2010 14547 http://www.biovalley.com/rssfeed.cfm?nid=14546 MILFORD, Mass. – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific Nunc Edge 96-well Plates for cell-based assays. The new Nunc™ Edge plates incorporate large perimeter evaporative buffer zones that eliminate well-to-well variability, while dramatically reducing the overall plate evaporation rate to <2 percent after 7 days of incubation. As a result, more viable and healthy cell yields are obtained. These zones enable the use of all 96 well... Fri, 30, Jul 2010 14546 http://www.biovalley.com/rssfeed.cfm?nid=14545 Imports of illegal medicines into Switzerland jumped by 75 per cent in the first half of this year – a situation causing concern among health officials. Products such as bogus Viagra remain the most popular, but there has also been a peak in the orders of slimming products, some of which are dangerous. Fri, 30, Jul 2010 14545 http://www.biovalley.com/rssfeed.cfm?nid=14544 INDIANAPOLIS -- Celebration Park has long been one of the busiest areas at the Indiana State Fair drawing in 4-H families, music lovers and fairgoers looking for a shady spot to rest. Now, visitors to this area in the northwest corner of the fairgrounds will see a new name attached to the park's locator signs: Dow AgroSciences. Fri, 30, Jul 2010 14544 http://www.biovalley.com/rssfeed.cfm?nid=14543 EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Robert F. Apple, EVP, CFO and President of the Parenteral Products Division will present at the BMO 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 8:30 a.m. ET (Eastern Time). Fri, 30, Jul 2010 14543 http://www.biovalley.com/rssfeed.cfm?nid=14542 FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the promotion of Vincent A. Forlenza, President, who assumes the title of Chief Operating Officer in addition to his current title. Mr. Forlenza will continue to report to Edward J. Ludwig, Chairman and Chief Executive Officer. Fri, 30, Jul 2010 14542 http://www.biovalley.com/rssfeed.cfm?nid=14541 CAMBRIDGE, Mass. -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Vito J. Palombella, Chief Scientific Officer, will present a company overview at the BMO 10th Annual Focus on Health Care Conference on Thursday, August 5, 2010 at 10:45 a.m. EDT in New York City. Fri, 30, Jul 2010 14541 http://www.biovalley.com/rssfeed.cfm?nid=14540 LUDWIGSHAFEN, Germany – The Board of Executive Directors of BASF SE announced the following changes in its organization and management team. In order to prepare for the integration of Cognis, BASF will establish a new division. Effective August 1, 2010, BASF’s Care Chemicals division will be split into two separate divisions: Fri, 30, Jul 2010 14540 http://www.biovalley.com/rssfeed.cfm?nid=14539 FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Zachary A. Nagle has joined the Company as Vice President, Investor Relations. In this role, Mr. Nagle will serve as the primary liaison between BD and its investors, analysts and the financial community globally. Fri, 30, Jul 2010 14539 http://www.biovalley.com/rssfeed.cfm?nid=14538 BETHESDA, Md. -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will sponsor a conference call to discuss its financial results for the second quarter ended June 30, 2010. These results are expected to be released on Thursday, August 5, 2010, after the capital markets close. The conference call will be hosted by senior management and will be held at 5:00 pm Eastern on Thursday, August 5, 2010. Fri, 30, Jul 2010 14538 http://www.biovalley.com/rssfeed.cfm?nid=14537 CARLSBAD, Calif. -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year. Fri, 30, Jul 2010 14537 http://www.biovalley.com/rssfeed.cfm?nid=14536 SAN FRANCISCO - A nonprofit environmental group has sued the U.S. Food and Drug Administration, claiming the agency failed to regulate toxic chemicals found in "antimicrobial" soap and other personal care products. Fri, 30, Jul 2010 14536 http://www.biovalley.com/rssfeed.cfm?nid=14535 DuPont 2Q earnings and business segment performance announcements Tuesday captured the attention of analysts and media around the world. The company’s strong 2Q performance was the lead business story for several influential global media outlets Tuesday, including The Wall Street Journal, Bloomberg, Reuters and Associated Press newswires. Fri, 30, Jul 2010 14535 http://www.biovalley.com/rssfeed.cfm?nid=14534 PENZBERG, Germany -- 454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection. The findings were outlined last month at the International HIV & Hepatitis Virus Drug Resistance Workshop in Dubrovnik, Croatia, and follow only weeks after the results from a similar multi-site research study, which used th... Thu, 29, Jul 2010 14534 http://www.biovalley.com/rssfeed.cfm?nid=14533 ABBOTT PARK, Illinois (NYSE: ABT) — Abbott today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR (niacin extended-release / simvastatin), a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin – the most commonly prescribed dose of simvastatin – with either 500 mg or 1,000 mg of niacin extended-release. SIMCOR is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most co... Thu, 29, Jul 2010 14533 http://www.biovalley.com/rssfeed.cfm?nid=14532 INDIANAPOLIS -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid. Thu, 29, Jul 2010 14532